EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S. Smolen*, Robert Landewe, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D. Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-HustingsPaul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M. W. Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poor, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, Rene Westhovens, Maarten de Wit, Desiree van der Heijde

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)960-977
Number of pages18
JournalAnnals of the Rheumatic Diseases
Volume76
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • ADALIMUMAB PLUS METHOTREXATE
  • INTERLEUKIN-6 RECEPTOR INHIBITION
  • RANDOMIZED CONTROLLED-TRIAL
  • PLACEBO-CONTROLLED TRIAL
  • TREAT-TO-TARGET
  • STANDARDIZED OPERATING PROCEDURES
  • RAPID RADIOGRAPHIC PROGRESSION
  • CARDIOVASCULAR RISK-MANAGEMENT
  • DOSE GLUCOCORTICOID THERAPY
  • ACUTE-PHASE REACTANTS

Cite this